Linked Life Data

20477266

Source:http://linkedlifedata.com/resource/pubmed/id/20477266

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-5-18
pubmed:abstractText
Tumor necrosis factor (TNF)-alpha is a proinflammatory cytokine. Blocking TNF-alpha has been demonstrated to be effective in various diseases, including both rheumatoid and psoriatic arthritis. There is evidence to show that levels of TNF-alpha are elevated in patients with severe asthma. TNF-alpha is involved in the initiation and perpetuation of the inflammatory process, epithelial damage and remodeling, and mucin hypersecretion. Furthermore, TNF-alpha polymorphism has also been reported in the asthmatic population. Based on the necessity for alternative treatments for asthmatics with severe disease and those who are particularly resistant to conventional asthma therapy, it has been shown that molecules targeted at blocking the effects of TNF-alpha probably constitute a considerable advance in the management of these difficult patients. This review focuses on the evidence of TNF-alpha axis upregulation in severe corticosteroid-refractory asthma, as well as the role of TNF-alpha inhibition and the adverse effects of treatment.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Aug
pubmed:issn
1747-6356
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
51-63
pubmed:year
2007
pubmed:articleTitle
Tumor necrosis factor-alpha in severe corticosteroid-refractory asthma.
pubmed:affiliation
Southampton General Hospital, Asthma Allergy Inflammation & Repair, Level F, South Academic Block, Mailpoint 810, Southampton SO16 6YD, UK. jbm@soton.ac.uk
pubmed:publicationType
Journal Article